trial

Pharmacological Approach to Improve the Outcome of Social Cognition Training

NCTId NCT01517360
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 27 (actual)
Sponsored by VA Greater Los Angeles Healthcare System
Primary completion 2013-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
27 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-01
Primary completion
2013-02
Eligibility
MALE · 18 Years · 55 Years

Interventions & indications

Drugs
OxytocinSocial Cognitive skills training

Sponsors

VA Greater Los Angeles Healthcare SystemLead Sponsor
National Alliance for Research in Schizophrenia and Affective DisordersCollaborator

Investigators

1
Stephen R. Marder, MDPrincipal Investigator

Sites

1 total
Los Angeles, United States

Facts & assertions

4 sourced
Enrollment
27
Phase
PHASE1
Primary Completion Date
2013-02
Status
COMPLETED
relationships
The graph out of here
drug
Oxytocin
drug
Social Cognitive skills training
drug
lead_sponsor
VA Greater Los Angeles Healthcare System
company
collaborator
National Alliance for Research in Schizophrenia and Affective Disorders
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Stephen R. Marder, MD
person